1. Croda International Plc 2001 Preliminary Results

2. Summary Recovery in quarter 4 Strong cash inflow of £37.7m Strong balance sheet Strategy is delivering success Outlook positive

3. Summary of continuing operations 20012000 £m £m Sales308.5307.3 ======== ========= Operating profit 37.144.2 Interest(5.3)(8.5) __________ __________ Pre-exceptional profit31.835.7 Exceptionals3.1- ___________ ___________ Profit before tax34.935.7 ======== ========= EBITDA52.658.0 ========= =========

4. Statistics 20012000 EPS normalised (p)15.719.0 Dividend per share (p)11.311.0 Cash flow per share (p)21.81.4 Dividend cover (x)1.41.7 Interest cover (x)7.05.3 Tax rate34.7%33.9%

5. Specific operating costs * £m 20012000 Depreciation and amortisation15.513.8 Pension costs4.24.0 * Continuing operations before exceptionals

6. UK pension costs Balance sheet 2001 Asset/(liability) before tax28.7(5.6) Deferred tax(8.6)1.7 _________ _______ Net asset/(liability)20.1(3.9) ======== ======= Estimated Profit and loss 2002 Within operating profit(2.8)(5.2) Financing-2.8 ________ ________ Net cost(2.8)(2.4) ======== ====== £mSSAP 24FRS 17

7. Cash Net cash inflow of £37.7m Net debt down to £63.6m Net interest charge £5.3m after one off credit of £0.3m on ACT repayment

8. Cash flow £m 20012000 Operating cash flow58.044.8 Interest(5.4)(8.6) Dividends(13.4)(12.3) Taxation(3.7)(13.8) __________ _______ Free cash flow35.510.1 Net Capex(23.1)(23.8) Own shares(1.3)(1.8) Acquisitions/Disposals26.635.8 __________ ________ Net cash flow37.720.3 __________ ________

9. Turnover change on prior year* VolumeCurrencyMix/Total Price % % % % H1-0.5+2.5+1.5+3.5 H2-3.5-2.5+3.5-2.5 Year-2.0-+2.5+0.5 * Continuing operations only

10. Sales by destination * United Kingdom61.820.064.421.0 Rest of Europe81.426.482.927.0 Americas96.031.196.931.5 Asia39.512.836.111.7 Rest of World29.89.727.08.8 _________ ________ ________ ________ 308.5100.0307.3100.0 _________ _________ ________ ________ * Continuing operations only 2001 2000 £m % £m %

11. Sales by market * Personal & Health Care155.450.4150.749.0 Home Care & Plastics Additives43.414.137.612.2 Industrial Specialities62.420.268.122.2 Other47.315.350.916.6 _________ ________ ________ ________ 308.5100.0307.3100.0 _________ ________ ________ ________ * Continuing operations only 20012000 £m% £m %

12. Summary of trading Sales held up in a difficult year Contribution rate maintained Positive mix effect particularly in second half Raw material prices stable Increase in cost base Some one-off costs

13. Oleochemicals 200020002000200120012001 FirstSecondYearFirst SecondYear halfhalfhalfhalf Turnover£m128.9127.5256.4134.2127.0261.2 Trading profit£m21.721.743.421.616.137.7 Margin%16.817.016.916.912.714.4

14. Strategic and operational progress

15. Singapore Profitable at the operating level Output rising (production volumes up 42% in 2001) Demand still growing Will break-even Q2 2002

16. Personal Care Crodamazon Sederma Other

17. Crodamazon Factory opened on time and on cost in Q4 2001 8 ingredients already in production including derivatives Range to be launched in Europe and USA in Spring First full year sales of £0.5m expected

18. Raw Materials

19. Crodamazon plant

20. Sederma Matrixyl now Sederma’s biggest selling product New anti-acne product produced from a combination of three ingredients to tackle the causes of acne (ac.net) Calmosensine - reduces skin irritation Beech sap - an energiser for male cosmetic lines

21. ac.net

22. Other Tissue coatings/wet wipes Hydrosolanum - Revolutionary low colour, low odour protein New patented UV protection for Hair Care New patented softener for Hair Care

23. Crodazosoft DBQ Increase in Softness

24. Health Care Provensis project update IBS Super High Purity Lipids Gelatin Asthma treatment

25. Asthma Pre-launch delivery will be early quarter two Launch date June 2002 Further orders expected for delivery in Q4

26. Short term outlook Q3 2001 was the low point Order intake rising Raw material prices overall marginally lower in 2002 Cost base now reducing

27. Medium term outlook Continued focus on Oleochemical Specialities Development of Health Care business Increased marketing of our expertise in speciality lipids Continued innovation in Personal Care Targetted acquisitions

28. Appendices Sales by market Segmental analysis of sales

29. Sales by market 2001 1998

30. Segmental analysis of sales 1991 2001